GBA vaccine R&D, transformation center opens in Huangpu

The plaque unveiling ceremony of the Guangdong-Hong Kong-Macao Greater Bay Area innovative vaccine technology industrial transformation center.

The Guangdong-Hong Kong-Macao Greater Bay Area innovative vaccine technology industrial transformation center unveiled its plaque in Huangpu district on April 26, striving to be a world-leading vaccine incubation platform. 

The center was jointly built by Guangzhou Regenerative Medicine and Health Guangdong Laboratory (Bioland Laboratory) and Yipinhong Pharmaceutical, boosting the development of downstream and upstream vaccine industries in the Greater Bay Area, as well as helping more scientists and innovative vaccine enterprises to carry out R&D and outcome transformation.

It will provide technical services as a contract development and manufacturing organization (CDMO) for small and medium-sized R&D institutes regarding biomedicine.

A staff member of the center noted that the center will focus on the industrial demands of the vaccine industry in the Greater Bay Area, as well as select outstanding domestic vaccine projects to provide services in outcome transformation and marketization in the Greater Bay Area.

Yipinhong Pharmaceutical is an innovative pharmaceutical enterprise dedicated to the R&D, manufacturing, and marketing of high-end medicines. It now has an R&D team of 261 members, led by global senior scientists. The team is currently working on more than 50 projects. 

Share - WeChat